VA
XENE icon

Vident Advisory’s Xenon Pharmaceuticals XENE Stock Holding History

Vident Advisory’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-6,574
Closed -$221K – 1711
2025
Q1 		$221K Buy
6,574
+1,161
+21% +$44.1K ﹤0.01% 1402
2024
Q4 		$212K Buy
+5,413
New +$224K ﹤0.01% 1324
2024
Q3 		– Sell
-7,082
Closed -$276K – 1575
2024
Q2 		$276K Sell
7,082
-719
-9% -$28.7K 0.01% 1153
2024
Q1 		$336K Buy
7,801
+2,509
+47% +$115K 0.01% 973
2023
Q4 		$244K Buy
+5,292
New +$187K 0.01% 1117

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vident Advisory's XENE Position: Q2 2025 in Review

Vident Advisory sold out of Xenon Pharmaceuticals (XENE) in Q2 2025, closing a stake of 6,574 shares — an estimated $221K sold.

Vident Advisory first reported a position in XENE in Q4 2023 and held it in 5 quarters. The position peaked at $336K in Q1 2024. 206 funds tracked by Wall St. Rank hold XENE as of Q2 2025.

  • Vident Advisory reported no remaining Xenon Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Vident Advisory sold 6,574 Xenon Pharmaceuticals shares in Q2 2025, an estimated $221K.
  • Vident Advisory first reported a position in Xenon Pharmaceuticals in Q4 2023 and held it in 5 quarters.
  • Vident Advisory's Xenon Pharmaceuticals position peaked at $336K in Q1 2024.
  • 206 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2025.

Based on Vident Advisory's 13F filing for Q2 2025, filed 14 Aug 2025.